08:15–08:45 |
Introductions and Welcome
James Cavuoto, Editor and Publisher, Neurotech Reports
Paru Deshpande, Ph.D., Vice President, R&D, Health Technologies, imec
|
08:45–09:30 |
State of the European Neurotechnology Industry, 2026
James Cavuoto, Editor and Publisher, Neurotech Reports
Neurotech Business Report Editor James Cavuoto provides his insights and observations on the state of the European neurotechnology industry. He surveys changes in the competitive landscape that have occurred over the years, the most significant events of the last year, and challenges confronting the industry in years ahead. |
09:30-10:15 |
Keynote Address
Thomas Stieglitz, Ph.D., Professor, University of Freiburg
A European neurotechnology pioneer offers his views on future directions in the industry. |
10:15–10:45 |
Coffee Break |
10:45–11:30 |
Neuromodulation Technology Advances
Jeremy Koff, Senior Consulting Editor, Neurotech Reports, Moderator
Will Pitkin, Senior Director of Business Development and Neuromodulation Strategy, Cirtec Medical
Rob Crawford, Senior Director of Sales and Marketing, MST
Omari Bouknight, CEO, Resonant Link Medical
Thorsten Göettsche, CTO, Osypka
In this session, we'll look at how new technology is changing the competitive landscape in the neuromodulation industry. Panelists will discuss advances in wireless energy delivery, flexible leads, and nanoparticles. |
11:30-12:15 |
Entrepreneur Panel I
James Cavuoto, Editor, Neurotech Reports, Moderator
Bert Monna, Ph.D., CTO, Phosphoenix B.V.
Karl Stoklosa, CEO, Precisis GmbH
Mark Caffrey, CEO, Syntropic Medical
This session features presentations from CEOs and executives of several neurotechnology start-up firms and more established technology ventures. Each executive will present an overview of their firm's technology and markets. |
12:15–13:30 |
Luncheon |
13:30-14:15 |
FemTech Meets Neurotech: An Underserved Market with Real TAM
JoJo Platt, Senior Contributing Editor, Neurotech Reports, Moderator
Daniel Chew, Ph.D., CEO and Co-founder, Artemis Medical
Hubert Martens, Ph.D., CEO, Salvia Bioelectronics
In this session, panelists will discuss new opportunities for neurotech devices in women's health. Among the applications are pelvic pain, endometriosis, and menopause-linked disorders.
|
14:15-15:00 |
From Neurotechnology Discovery to Clinical-Scale Systems
Carolina Mora Lopez, Ph.D., Scientific Director of Neurotech, imec
An imec technology leader offers an overview of the evolution of neurotechnology at imec, from Neuropixels to current high-density ASICs, highlighting platform development over time.
|
15:00-15:30 |
Refreshment Break |
15:30-16:15 |
BCI Leaders of Europe
JoJo Platt, Senior Contributing Editor, Neurotech Reports, Moderator
Fabien Sauter, Ph.D., Project Manager, CEA Clinatec
Luke Bashford, Ph.D., Scientific Director, UK National Centre for Neurotechnology and Neurorestoration
Dan Gnansia, Ph.D., Head of Clinical, INBRAIN Neuroelectronics
JoJo Platt moderates a panel with some of Europe's leading commercial firms pursuing the market for brain-computer interfaces.
|
16:30-17:30 |
Lab and Cleanroom Tours
|
17:30–20:00 |
Networking Reception
|
08:30–08:45 |
Introductions and Welcome |
08:45–09:30 |
Venture Capital Investment: What's Getting Funded?
James Cavuoto, Editor, Neurotech Reports, Moderator
Diana Saraceni, Co-founder and Managing Partner, Panakes Partners
Ugo Tomasello, Ph.D., Co-founder and General Partner, European BrainTech Fund
Mario Huyghe, Senior Venture Development Manager, imec
Jan Debets, Head of Business Development & Partnerships, META Group
Neurotech Business Report Editor James Cavuoto moderates a panel with leading venture capital firms active in Europe that fund neurotechnology ventures. Panelists will discuss factors such capital efficiency, platform narratives, and determining valuations.
|
09:30-10:15 |
Regulatory Divergence is Now a Strategy Choice
Jeremy Koff, Senior Consulting Editor, Neurotech Reports, Moderator
Jacek Eisler, Neuro Market Segment Manager, TUV SUD
Lindsey Jardine, Vice President, Clinical, Regulatory, Quality Affairs, Adraxe
Martin Becker, Neuro Market Segment Manager, cpi
In this session, panelists will discuss important regulatory decisions that neurotech firms must make, including the timing of FDA vs. CE Mark applications, updates on EU MDR policies, and the value of pursuing breakthrough device designation.
|
10:15–10:45 |
Coffee Break |
10:45–11:30 |
Neurotech Europe on the World Stage: Strategy, Scale, and Global Integration
JoJo Platt, Senior Contributing Editor, Neurotech Reports, Moderator
Mark Vlek de Coningh, Secretary General, Neurotech EU
François Véron, General Partner, Newfund
Stephen Hicks, Science and Technology Lead, ARIA
Europe’s neurotechnology sector has reached a critical inflection point. While rich in scientific talent and early innovation, there are still opportunities for growth in scale, capital efficiency, and global market influence. This session brings together leaders from across Europe to examine what’s working, what’s broken, and where Europe risks falling behind. The discussion will focus on levers for growth including regulatory alignment, reimbursement pathways, capital formation, and industry coordination in order to position Europe as a competitive, globally integrated neurotech powerhouse. |
11:30-12:15 |
Entrepreneur Panel II
James Cavuoto, Editor, Neurotech Reports, Moderator
Olivier Menage, D. Pharm, CEO, Stimalia
Luca Ravagnan, Ph.D., CEO and Co-founder, WISE
Eliot Frazier, CEO, SONA
This session features presentations from CEOs and executives of several neurotechnology start-up firms and more established technology ventures. Each executive will present an overview of their firm's technology and markets. |
12:15–13:30 |
Luncheon |
13:30-14:15 |
Entrepreneur Panel III
Jeremy Koff, Senior Consulting Editor, Neurotech Reports, Moderator
Frederik Ceyssens, CEO, ReVision Implant
Michael Pare, CEO, Melora Medical
Stéphane Corp, CEO, Deep Pulse Neuro
This session features presentations from CEOs and executives of several neurotechnology start-up firms and more established technology ventures. Each executive will present an overview of their firm's technology and markets. |
14:15-15:00 |
Beyond the Brain: Peripheral, Autonomic, and Systemic Control
Victor Pikov, Contributing Editor, Neurotech Reports, Moderator
Sean Doherty, Ph.D., Director of R&D, Amber Therapeutics
Jiande Chen, Ph.D., Director of Neuromodulation, Division of Gastroenterology, University of Michigan
Omar Shalby, CEO and Co-founder, Neurovia Srl
In this session, we look at applications of neuromodulation beyond the central nervous system, including therapies for treating systemic and end-organ disorders. Panelists will discuss new closed-loop vagus nerve and pelvic neuromodulation trends and new reimbursement developments. |
15:00-15:30 |
Refreshment Break |
15:30-16:15 |
Enabling Neuromodulation Research with Advanced Stimulation & Closed Loop Paradigms
In this session, an imec executive offers an overview of recent advances in neuromodulation technologies at imec, highlighting neural stimulation approaches and closed-loop paradigms for next-generation brain–technology interfaces.
Vojkan Mihajlovic, Ph.D., Principal Scientist, imec
|
16:15-17:15 |
Closing Remarks
|
|
|